Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience

Authors

  • Wei Jing Loo, BSc, MBBS, MRCP, FRCP University of Western Ontario, London, ON

DOI:

https://doi.org/10.58931/cdt.2025.61135

Abstract

Acne vulgaris is a globally prevalent dermatological condition associated with a substantial physical and psychological burden.

This case series includes 10 patients with acne vulgaris who received treatment with clascoterone cream 1% from August 2023 to May 2024. Treatment with clascoterone cream 1% was effective and well tolerated regardless of acne severity, age, gender, and ethnicity. Clascoterone led to clinical improvement when used as monotherapy, as an adjunctive treatment in combination with other topical or systemic agents or laser therapy, and as maintenance therapy to prevent acne relapse. Moreover, clascoterone helped address other concerns in several patients, including hirsutism, hidradenitis suppurativa, retinoid-induced dermatitis, androgenetic alopecia, folliculitis, and laser‑induced acne flares. This recent real-world clinical experience supports the effectiveness, tolerability, and versatility of clascoterone cream 1% for patients with acne vulgaris across a variety of clinical and demographic characteristics.

Author Biography

Wei Jing Loo, BSc, MBBS, MRCP, FRCP, University of Western Ontario, London, ON

Dr. Wei Jing Loo is the owner and Medical Director of DermEffects, a cutting edge dermatology centre located in London, Ontario. Dr. Loo completed medical school in 1997 with an honours degree from the University of New South Wales in Sydney, Australia. She trained in Internal Medicine and obtained membership in the Royal College of Physicians in the United Kingdom in 1999. She completed her dermatology residency training in Cambridge, United Kingdom and obtained her Certificate of Specialist Training in Dermatology in 2005. She is board certified in Canada and a fellow of the Royal College of Physicians and Surgeons of Canada. She is a member of the Canadian Dermatology Association and American Academy of Dermatology. Dr. Loo is at the forefront of the dynamic field of dermatology, serving as an associate investigator for Probity Medical Research. Dr. Loo is an Adjunct Professor at Western University in Ontario. She enjoys teaching and has published her work in many peer-reviewed journals.

References

Reynolds RV, Yeung H, Cheng CE, Cook-Bolden F, Desai SR, Druby KM, et al. Guidelines of care for the management of acne vulgaris. J Am Acad Dermatol. 2024;90(5):1006.e1001–1006.e1030. doi:10.1016/j.jaad.2023.12.017

WINLEVI® (clascoterone cream 1%). Sun Pharma Canada Inc., Brampton, Ontario: Product Monograph. [Updated June 15, 2023, Cited January 9, 2025]. Available from: https://pdf.hres.ca/dpd_pm/00071308.PDF

WINLEVI® (clascoterone cream 1%). Sun Pharmaceutical Industries, Inc. Cranbury, NJ: Full Prescribing Information. [Updated March 1, 2023, Cited January 9, 2025]. Available from: https://www.drugs.com/pro/winlevi.html

Hebert A, Thiboutot D, Stein Gold L, Cartwright M, Gerloni M, Fragasso E, et al. Efficacy and safety of topical clascoterone cream, 1%, for treatment in patients with facial acne: two phase 3 randomized clinical trials. JAMA Dermatol. 2020;156(6):621–630. doi:10.1001/jamadermatol.2020.0465

Chu L, Gold S, Harris C, Lawley L, Gupta P, Tangpricha V, et al. Incidence and factors associated with acne in transgender adolescents on testosterone: a retrospective cohort study. Endocr Pract. 2023;29(5):353–355. doi:10.1016/j.eprac.2023.02.002

Radi R, Gold S, Acosta JP, Barron J, Yeung H. Treating acne in transgender persons receiving testosterone: a practical guide. Am J Clin Dermatol. 2022;23(2):219–229. doi:10.1007/s40257-021-00665-w

Mazzetti A, Moro L, Gerloni M, Cartwright M. Pharmacokinetic profile, safety, and tolerability of clascoterone (cortexolone 17-alpha propionate, CB-03-01) topical cream, 1% in subjects with acne vulgaris: an open-label phase 2a study. J Drugs Dermatol. 2019;18(6):563.

Lynde C, Abdulla S, Andriessen A, Hanna S, Jafarian F, Li M, et al. Real-world cases of clascoterone topical treatment for acne and related disorders. J Drugs Dermatol. 2025;24:1(Supple 2):s3-14. doi: 10.36849/JDD.73361

Cunningham KN, Moody K, Alorainy M, Rosmarin D. Use of topical clascoterone for the treatment of hidradenitis suppurativa. JAAD Case Rep. 2023;36:38–39. doi:10.1016/j.jdcr.2023.04.002

Der Sarkissian SA, Sun HY, Sebaratnam DF. Cortexolone 17alpha-propionate for hidradenitis suppurativa. Dermatol Ther. 2020;33(6):e14142. doi:10.1111/dth.14142

Hargis A, Yaghi M, Maskan Bermudez N, Lev-Tov H. Clascoterone in the treatment of mild hidradenitis suppurativa. J Am Acad Dermatol. 2024;90(1):142–144. doi:10.1016/j.jaad.2023.08.064

Sun HY, Sebaratnam DF. Clascoterone as a novel treatment for androgenetic alopecia. Clin Exp Dermatol. 2020;45(7):913–914. doi:10.1111/ced.14292

Cartwright M, Mazzetti A, Moro L, Caridad R, Gerloni M. A summary of in vitro, phase I, and phase II studies evaluating the mechanism of action, safety, and efficacy of clascoterone (cortexolone 17a propionate, CB-03-01) in androgenetic alopecia. J Am Acad Dermatol. 2019;81(4):AB13. doi:10.1016/j.jaad.2019.06.087

Published

2025-03-07

How to Cite

1.
Loo WJ. Clascoterone Cream 1% in Acne Management: Case Series and Real-World Canadian Experience. Can Dermatol Today [Internet]. 2025 Mar. 7 [cited 2025 Mar. 22];6(1):22–27. Available from: https://canadiandermatologytoday.com/article/view/6-1-Loo

Issue

Section

Articles